What Klaricid-R Treats: Main Uses and Benefits

The therapeutic benefit of the macrolide antibiotic clarithromycin is used across domains involving certain bacterial infections. It is applied in clinical settings that involve acute or unstable symptom patterns for susceptible bacterial pathogens.

Klaricid-R is commonly used to help address conditions associated with bacterial infection of the respiratory tract, including Community-Acquired Pneumonia, acute exacerbations of chronic bronchitis, and acute maxillary sinusitis. It is also considered relevant in conditions where symptoms may intensify temporarily due to skin and soft tissue infections and specific therapeutic efforts aimed at managing H. pylori in peptic ulcers.

“The medicine is applied when symptoms create noticeable functional strain during acute infectious phases.”

It is relevant for managing symptom clusters that interfere with daily comfort, such as productive cough, facial pressure, fever, and localized redness and swelling. This treatment supports patients during episodes of heightened discomfort by easing the overall symptom burden, contributes to easing the overall symptom load during these symptomatic periods.

---

Quick Fact: Relief for Acute Respiratory Symptoms The medication is relevant in clinical settings that involve acute or unstable symptom patterns associated with the sudden onset of bacterial respiratory and sinus infections.

Eligibility Map: Who can and cannot use Klaricid-R — official regulatory information

Eligibility scope

Populations for whom use is allowed (as stated in label):

• Adults and adolescents 12 years and older.

Populations for whom use is contraindicated:

• Patients with a known allergy to clarithromycin, erythromycin, or any macrolide antibiotic.
• Individuals with a history of QT prolongation (a specific heart rhythm disorder) or ventricular cardiac arrhythmia.
• Individuals with severe hepatic failure combined with renal impairment (kidney disease).
• Patients with low potassium (hypokalaemia) or low magnesium (hypomagnesaemia) in the blood.
• Patients with a history of cholestatic jaundice or liver dysfunction associated with prior clarithromycin use.
• Concurrent use with specific medications is strictly contraindicated (e.g., cisapride, pimozide, ergot alkaloids, lovastatin, simvastatin, lurasidone, or colchicine in patients with kidney or liver impairment).

Age and Condition-specific Eligibility

• Children: The tablet formulation is not recommended for children under 12 years of age; other forms are available for this age group.
• Renal Impairment: Use of the modified-release tablet is contraindicated in patients with a creatinine clearance less than 30 mL/min because the dosage cannot be appropriately reduced.
• Pregnancy/Lactation: Use is generally not recommended during pregnancy unless alternatives are unavailable; nursing should be discontinued during treatment.

Klaricid-R (Clarithromycin) is a potent inhibitor of the CYP3A4 enzyme, which is a major metabolic pathway for many other medications. This inhibition can lead to significantly increased levels of the co-administered drugs in the body, raising the risk of serious side effects or toxicity.

Contraindicated Combinations

The use of Klaricid-R is strictly avoided with certain medications due to the high risk of severe adverse reactions. These include:

• Certain Statins: Lovastatin and Simvastatin, as the combination can increase the risk of muscle damage, including rhabdomyolysis.
• Ergot Alkaloids: Ergotamine or Dihydroergotamine, due to the risk of acute ergot poisoning, which involves blood vessel constriction and potential tissue ischemia.
• Specific Antiarrhythmics and other drugs: Astemizole, Cisapride, Pimozide, Terfenadine, Domperidone, Colchicine (in patients with kidney or liver impairment), Oral Midazolam, Ticagrelor, Ivabradine, Ranolazine, and Lomitapide. Co-administration with these drugs is contraindicated because it can cause QT prolongation and dangerous heart rhythm changes, such as Torsades de Pointes.

Other Significant Interactions

Caution and typically a dose adjustment or close monitoring are necessary when Clarithromycin is co-administered with other drugs that are CYP3A4 substrates or those that affect the QT interval. These include Oral Anticoagulants (such as Warfarin), Digoxin, Quinidine, Disopyramide, Theophylline, Carbamazepine, and Phosphodiesterase Inhibitors ( Sildenafil, Tadalafil, Vardenafil). Conversely, drugs that induce CYP3A4 (e.g., Rifampicin) can decrease Clarithromycin levels, potentially reducing its effectiveness. Zidovudine may need to be spaced at least 2 hours apart from Clarithromycin for optimal absorption.

The mechanism of action for Clarithromycin (Klaricid-R) operates primarily through two distinct biological domains that collectively contribute to the pharmacological action against the pathogen.

Direct Inhibition of Bacterial Protein Synthesis

This mechanism is initiated by the drug's binding to the 50S ribosomal subunit within susceptible bacteria, which prevents the essential processes of peptide chain elongation and protein assembly. By halting the creation of vital microbial proteins, this action immediately imposes a bacteriostatic effect, which is the physiological consequence of inhibited protein biogenesis.

Modulation of Host Inflammation

Beyond its direct antimicrobial properties, Clarithromycin engages a secondary mechanism that modulates the host's inflammatory cascade. This action involves influencing the release of key pro-inflammatory signaling molecules (cytokines) from host immune cells. This effect helps to dampen excessive inflammatory responses, which complements the primary action of limiting bacterial proliferation and contributes to the systemic stabilization of the physiological response.

Official Administration Guidelines for Klaricid-R (Extended-Release)

Klaricid-R is the modified-release tablet formulation of the antibiotic clarithromycin, and its administration is strictly defined by regulatory guidelines to ensure the correct slow-release action. The approved method of use is the oral route.

Usage Parameter	Official Regulatory Instruction
Route of Administration	Oral (by mouth).
Standard Adult Dose	1 gram (1000 mg) per day, usually as two 500 mg tablets.
Frequency	Once daily (every 24 hours), ideally at the same time each day.
Administration Condition	Must be taken with food to ensure adequate absorption; administration in a fasting state can reduce the amount of absorbed drug.
Course Duration	The length of treatment is typically 7 to 14 days, based on the specific condition being addressed.

Procedural instructions are mandatory for the modified-release formulation. The tablet must be swallowed whole and must not be chewed, broken, or crushed under any circumstances, as this action would compromise the extended-release mechanism.

Population-Specific Rules

The extended-release form is not approved for use in children under 12 years of age; a different formulation (such as a pediatric suspension) must be used for this population. Furthermore, the tablet is contraindicated in patients with a creatinine clearance less than 30 mL/min because the required dosage reduction cannot be achieved with the 500 mg minimum tablet strength. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped.

Research evidence / Overview of studies for Klaricid-R

This overview describes the research landscape for Klaricid-R (clarithromycin extended-release), detailing the types of studies conducted and what their findings indicate, based on peer-reviewed scientific literature and regulatory documents. The text focuses on the structure and conclusions of the evidence without providing medical advice, instructions, or safety information.

---

Evidence for Use in Acute Respiratory Infections

Research has extensively explored the use of Klaricid-R for conditions characterized by fluctuating or episodic manifestations of infection in the respiratory tract. This includes studies relevant in trials assessing short-term or episodic symptom patterns linked to conditions like Community-Acquired Pneumonia (CAP) and Acute Exacerbation of Chronic Bronchitis (AECB).

Short-term Randomized Controlled Trials (RCTs) was the main study type used to evaluate the medicine. These studies primarily focused on adult populations experiencing acute conditions, most often involving patients in ambulatory (non-hospitalized) care settings. The outcomes monitored included observed patterns of change in acute symptoms and the percentage of patients whose infection was assessed as bacteriologically eliminated. For both CAP and AECB, comparative research data show patterns related to patient-reported outcomes related to discomfort that were observed in trials comparing it to other treatments.

Research on Acute Maxillary Sinusitis

Research for acute maxillary sinusitis was evaluated in controlled multicenter studies that focused on conditions associated with acute or disruptive episodes. These studies involved adults and adolescents with confirmed sinus infection. Researchers carefully examined several outcomes, including patient-reported outcomes describing perceived discomfort, the assessment of clinical response, and radiological success confirmed through imaging. While the research provides insight into short-term changes, follow-up durations were limited to the acute phase and immediate post-treatment period.

---

Research on Specific Bacterial Targets

Research has examined clarithromycin’s role in multi-drug regimens targeting specific bacteria, such as H. pylori, which is relevant in evidence describing how symptoms are measured in conditions marked by functional limitations like peptic ulcers. The regulatory literature indicates that the extended-release formulation may not be the most appropriate choice for use in these specific multi-drug regimens, based on comparisons with other forms of clarithromycin. Data for this particular group remain insufficient.

Key Studies & References Clarithromycin extended-release tablets - Label - DailyMed (FDA)

Common questions about Klaricid-R (FAQ)

---

Q: What is the main ingredient in Klaricid-R?

The active ingredient in Klaricid-R is the antibiotic clarithromycin. This substance is responsible for the therapeutic action of the tablet.

Q: Is Klaricid-R used to treat common colds?

Klaricid-R is an antibiotic, meaning it is used to treat specific infections caused by susceptible bacteria. Common colds are typically viral and are not listed as an official indication for this medicine.

Q: What type of infections is Klaricid-R typically prescribed for?

According to the official product information, indications for clarithromycin include, but are not limited to, certain upper and lower respiratory tract infections (such as community-acquired pneumonia). It is also used for uncomplicated skin and skin structure infections and is indicated as part of a combination regimen for H. pylori infection.

Q: Does Klaricid-R treat ear infections?

Clarithromycin is indicated for certain upper respiratory tract infections, which may include specific types of ear infections (otitis media). Its use is based on its efficacy against specific types of bacteria.

Q: Why is this version called Klaricid-R instead of just Klaricid?

The '-R' indicates that this is the extended-release (or modified-release) tablet formulation of clarithromycin. This formulation is designed to allow the drug to be taken once daily.

Q: Does taking Klaricid-R cause stomach upset often?

Gastrointestinal adverse reactions are listed among the most frequent side effects reported in clinical trials. These may include nausea, diarrhea, vomiting, and abdominal pain.

Q: Are headaches a common side effect of Klaricid-R?

Yes, headache is listed as a common adverse reaction, as reported in clinical trials.

Q: What are the most serious side effects mentioned in official documents for Klaricid-R?

Serious warnings in official documents include the risk of QT prolongation (a heart rhythm problem), Hepatotoxicity (liver problems, which can be fatal in rare cases), and severe allergic reactions like anaphylaxis.

Q: Can Klaricid-R affect the taste in your mouth?

An abnormal or altered sense of taste (dysgeusia or taste perversion) is a reported and relatively common side effect of clarithromycin.

Q: Can you take Klaricid-R if you are allergic to penicillin?

The use of Klaricid-R is contraindicated (not to be used) in patients with a known hypersensitivity or allergy to clarithromycin or any other macrolide antibiotic.

Q: Do you have to avoid alcohol while using Klaricid-R?

Official drug labeling does not list a specific contraindication for the use of alcohol while taking clarithromycin.

Q: What medicines are known to interact significantly with Klaricid-R?

Clarithromycin is a potent inhibitor of the CYP3A4 enzyme. This mechanism can cause significantly increased levels of many co-administered medicines, including certain antiarrhythmics and blood pressure drugs, thereby increasing the risk of serious adverse effects.

Q: Can Klaricid-R be used by patients with heart problems?

Official warnings advise that clarithromycin should be avoided in patients with a history of QT prolongation or other ventricular cardiac arrhythmias. The warning is due to the potential risk of heart rhythm problems.

Q: Is Klaricid-R known to interact with blood thinners?

Official documents describe that clarithromycin may interact with certain oral anticoagulants (blood thinners), which can potentially lead to an increase in the risk of bleeding.

Q: Can people with liver issues use Klaricid-R?

Clarithromycin should not be used in patients who have severe hepatic failure (liver failure) combined with kidney impairment. The official product information notes that use in patients with pre-existing liver disease warrants caution.

Q: Is Klaricid-R safe to use during pregnancy, according to official classifications?

Official documents advise that clarithromycin should only be used during pregnancy when there are no safer alternatives available. Use is generally considered when the potential benefit to the mother is considered to outweigh the potential risk to the fetus.

Q: Why is it important to finish the full course of Klaricid-R?

Official guidance on antibiotic therapy notes that stopping treatment prematurely or taking an incomplete course may result in the development of bacteria that are resistant to the medicine. Following the prescribed course is intended to minimize the risk of incomplete treatment.

Q: Is antibiotic resistance a concern with Klaricid-R?

As with other antibiotics, official warnings state that long-term use of clarithromycin may result in the selection and growth of non-susceptible bacteria and fungi.

Q: Does Klaricid-R cause dizziness or drowsiness?

Yes, official documents list side effects such as dizziness, sleepiness, and vertigo (a spinning sensation) as reported adverse reactions.

Q: Is Klaricid-R commonly used for skin infections?

Yes, the official indication for clarithromycin includes the treatment of uncomplicated skin and skin structure infections caused by susceptible organisms.

Q: What research evidence supports the use of Klaricid-R for the listed infections?

Official drug documents include a Clinical Studies section that summarizes the research trials supporting the drug's effectiveness and safety for its approved uses. This section provides the foundation for regulatory approval.

Q: Do studies suggest Klaricid-R is useful for Helicobacter pylori (H. pylori)?

Yes, clarithromycin is officially indicated for use as part of a combination regimen (often with other medications) to treat patients with H. pylori infection and duodenal ulcer disease.

Q: What happens if you have a known kidney problem and take Klaricid-R?

Clarithromycin is primarily removed from the body by the kidneys. The extended-release tablet is contraindicated (not to be used) for patients with severe kidney problems (low kidney clearance) because the required dosage reduction cannot be achieved with this specific formulation.

Q: Is it normal to feel tired while taking Klaricid-R?

Unusual tiredness or weakness are among the general side effects that have been reported in official product information with the use of clarithromycin.

Q: What are the official recommendations for storage of Klaricid-R?

Official recommendations advise storage at room temperature, typically between 68°F to 77°F ( 20°C to 25°C). It is also generally recommended to protect the tablets from light and moisture.

Q: Can I use Klaricid-R if I have a history of colitis?

Official warnings state that almost all antibiotics, including clarithromycin, carry a risk of Clostridioides difficile-associated diarrhea (CDAD), which can lead to colitis. Official warnings note that this condition can range from mild to severe.

Q: Are there any long-term effects of taking Klaricid-R?

Official warnings describe a potential increased risk of death (of any reason) for patients with coronary artery disease that may persist for 1 to 10 years after taking the drug. This specific warning is noted in the drug’s official regulatory documents.

Q: Does Klaricid-R have a warning about interaction with colchicine?

Yes, concomitant administration of clarithromycin and colchicine is contraindicated (strictly avoided) in official documents due to the risk of increased colchicine exposure and potential toxicity.

Q: Can Klaricid-R be used for children?

The extended-release tablet formulation (Klaricid-R) is not approved for use in children under 12 years of age. However, clarithromycin is available in different formulations (like an oral suspension) that are approved for use in younger pediatric patients.

Q: Are mental or mood changes noted as side effects of Klaricid-R in official sources?

Yes, official documents list various psychiatric adverse reactions, including hallucinations, psychotic disorders, confusional state, and abnormal behavior or dreams.

Q: Does Klaricid-R affect blood sugar levels?

Official side effect documents list hypoglycemia (low blood sugar) as a reported adverse reaction. This adverse effect may be especially relevant for individuals taking other medications that affect glucose levels.

Q: What regulatory classifications exist for Klaricid-R regarding its safety in breastfeeding?

Clarithromycin is known to pass into breast milk in small amounts. The official documents state that a risk-benefit assessment is warranted before administration to a nursing mother.

Q: Is it common for Klaricid-R to cause diarrhea?

Diarrhea is listed as one of the most frequent side effects reported in clinical trials for clarithromycin, as reported in clinical trials. This is a common effect observed with many antibiotics.

Q: How is the extended-release (R) formulation different from the immediate-release form?

The primary difference is the release mechanism of the medicine. The extended-release form allows the dose to be taken once daily, while the immediate-release form is usually taken more frequently. The extended-release tablet must also be swallowed whole with food.

Q: What are the ingredients (excipients) in Klaricid-R tablets?

The official documents contain a dedicated section that lists all ingredients, including the active ingredient (clarithromycin) and the inactive ingredients, also known as excipients.

Q: Can Klaricid-R be used to prevent infections?

Clarithromycin is officially indicated for the prevention and treatment of disseminated Mycobacterium avium complex (MAC) disease in certain patient populations. For other infections, it is typically used for treatment.

Q: How is Klaricid-R eliminated from the body?

Following absorption, clarithromycin is processed in the body through both the liver (metabolized) and the kidneys (excreted). It is eliminated from the body through both renal (kidney) and non-renal (hepatic) routes.

How to Store and Dispose of Klaricid-R?

The storage and disposal of Klaricid-R (Clarithromycin extended-release tablets) must adhere strictly to official regulatory guidelines to preserve the medicine's integrity and ensure safety.

---

Official Storage Requirements

Condition	Instruction
Temperature	Store at controlled room temperature (68 F to 77 F or 20 C to 25 C).
Protection	Keep from freezing and protect from excess heat, light, and moisture.
Container	Must be kept in the original container and kept tightly closed.
Safety	Store out of the sight and reach of children.

---

Official Disposal Rules

Unused or expired Klaricid-R should not be kept. Regulatory instructions prohibit flushing the tablets down the toilet or pouring them down a drain. The official method is to dispose of the medicine through a drug take-back program. As an alternative, the tablets may be mixed with an unappealing substance like dirt or coffee grounds, sealed in a bag, and discarded in the household trash.